Astrazeneca ADR Stock
Price
Target price
€71.00
€71.00
0.000%
-
0.000%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Astrazeneca ADR Stock
There is no change in the price for Astrazeneca ADR today.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Astrazeneca ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Astrazeneca ADR in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Astrazeneca ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astrazeneca ADR | 0.000% | -1.389% | 10.078% | 2.158% | 15.447% | 53.348% | - |
| GSK plc ADR | -0.480% | -1.429% | 11.892% | 25.455% | 23.214% | 2.222% | -5.802% |
| Bayer AG ADR | -2.130% | -0.719% | 9.524% | -48.120% | -19.767% | -49.265% | -52.083% |
| Roche Holding AG ADR | 0.980% | 4.993% | 5.711% | -18.488% | -6.712% | -12.968% | - |
News
Forget Johnson & Johnson: Buy This Better Healthcare Stock Instead
Many healthcare investors look at Johnson & Johnson (NYSE: JNJ) and see a good, safe dividend stock. But I see an investment that's full of uncertainty and risk.
The company continually runs into
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
AstraZeneca Plc (NASDAQ: AZN)Q1 2024 Earnings CallApr 25, 2024, 6:45 a.m. ET
Operator
Source Fool.com
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
Weight-loss drugs are hot. Just look at the recent performances of Eli Lilly (NYSE: LLY), which won U.S. approval in November for Zepbound, and Novo Nordisk (NYSE: NVO), which markets Ozempic and